These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6164251)

  • 1. Serotonin and noradrenaline uptake inhibitors in the treatment of depression--relationship to 5-HIAA in spinal fluid.
    Träskman-Bendz L; Asberg M; Bertilsson L
    Acta Psychiatr Scand Suppl; 1981; 290():209-18. PubMed ID: 6164251
    [No Abstract]   [Full Text] [Related]  

  • 2. Triple uptake inhibitors: therapeutic potential in depression and beyond.
    Chen Z; Skolnick P
    Expert Opin Investig Drugs; 2007 Sep; 16(9):1365-77. PubMed ID: 17714023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs.
    Maas JW; Koslow SH; Katz MM; Bowden CL; Gibbons RL; Stokes PE; Robins E; Davis JM
    Am J Psychiatry; 1984 Oct; 141(10):1159-71. PubMed ID: 6207736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine.
    Asberg M; Ringberger VA; Sjöqvist F; Thorén P; Träskman L; Tuck JR
    Clin Pharmacol Ther; 1977 Feb; 21(2):201-7. PubMed ID: 13959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biogenic amine hypotheses of affective disorders.
    Garver DL; Davis JM
    Life Sci; 1979 Jan; 24(5):383-94. PubMed ID: 372718
    [No Abstract]   [Full Text] [Related]  

  • 6. A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. II. Biochemical findings.
    Aberg-Wistedt A; Ross SB; Jostell KG; Sjöquist B
    Acta Psychiatr Scand; 1982 Jul; 66(1):66-82. PubMed ID: 6181652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The benefits and risks of 5-HT uptake inhibitors in depression.
    Montgomery SA
    Br J Psychiatry Suppl; 1988 Sep; (3):7-10. PubMed ID: 2471570
    [No Abstract]   [Full Text] [Related]  

  • 8. 5-hydroxytryptamine and depression: a model for the interaction of normal variance with pathology.
    Goodwin FK; Post RM
    Br J Clin Pharmacol; 1983; 15 Suppl 3(Suppl 3):393S-405S. PubMed ID: 6190490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of selective 5HT reuptake inhibitors in comparison with tricyclic antidepressants.
    Kragh-Sørensen P; Le Fèvre Honoré P; Gram LF
    Psychopharmacol Ser; 1987; 3():147-56. PubMed ID: 3547394
    [No Abstract]   [Full Text] [Related]  

  • 10. Tricyclic antidepressant washout effects on cerebrospinal fluid and urinary monoamine and metabolites.
    Koslow SH; Maas JW; Bowden CL; Davis JM; Hanin I; Javaid J
    Arch Gen Psychiatry; 1986 Oct; 43(10):1012-3. PubMed ID: 2428327
    [No Abstract]   [Full Text] [Related]  

  • 11. [Development of biological psychiatric depression research (author's transl)].
    Matussek N
    MMW Munch Med Wochenschr; 1981 May; 123(19):793-4. PubMed ID: 6262640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls.
    Davis JM; Koslow SH; Gibbons RD; Maas JW; Bowden CL; Casper R; Hanin I; Javaid JI; Chang SS; Stokes PE
    Arch Gen Psychiatry; 1988 Aug; 45(8):705-17. PubMed ID: 2456047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatments for depression.
    Kent S
    Geriatrics; 1982 Nov; 37(11):149-51. PubMed ID: 6982191
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of depression with tricyclic drugs--pharmacokinetic and pharmacodynamic aspects.
    Asberg M
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jan; 9(1):18-26. PubMed ID: 10583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites.
    Potter WZ; Scheinin M; Golden RN; Rudorfer MV; Cowdry RW; Calil HM; Ross RJ; Linnoila M
    Arch Gen Psychiatry; 1985 Dec; 42(12):1171-7. PubMed ID: 2416297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of depressive disorders].
    Saiz Ruiz J; Ibáñez Cuadrado A
    Rev Clin Esp; 1997 Nov; 197 Suppl 3():35-43. PubMed ID: 9477689
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug treatment of anxiety and depression.
    Fox T
    Practitioner; 1991 Sep; 235(1506):681-3. PubMed ID: 1796034
    [No Abstract]   [Full Text] [Related]  

  • 18. Recent advances in psychopharmacology of depression.
    Johnson GF
    Aust N Z J Psychiatry; 1981 Sep; 15(3):223-7. PubMed ID: 6174112
    [No Abstract]   [Full Text] [Related]  

  • 19. SSRIs and tricyclic antidepressants.
    Ashworth LJ; Wilson KC
    Br J Psychiatry; 1993 Mar; 162():426. PubMed ID: 8453449
    [No Abstract]   [Full Text] [Related]  

  • 20. 5-HT uptake inhibitors and tricyclic antidepressants: relation between tryptophan availability and clinical response in depressed patients.
    Møller SE
    Eur Neuropsychopharmacol; 1990 Nov; 1(1):41-4. PubMed ID: 2136212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.